Daniel Harrison is a Neurology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
16 S Eutaw Street
3rd Floot
Baltimore, MD 21201
Telephone
410-328-3894Registry record last updated 7 May 2015.
Clinical trials
- OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis
Sponsor: University of Maryland, Baltimore
- Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
Sponsor: University of Maryland, Baltimore
- Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Sponsor: University of Maryland, Baltimore
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20251 payment
- TG Therapeutics, Inc.Program year20241 payment
- GENZYME CORPORATIONProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.2%Other immunostimulants15.5%Copaxone56%Glatopa28%Glatiramer Acetate16%Part D<11 patientsOther immunosuppressants5.9%Dimethyl Fumarate52%Tecfidera48%Part D<11 patients+ 5 more classes in this area
Nervous system
38.6%Benzodiazepine10%Clonazepam61%Alprazolam39%Part D<11 patientsPotassium Channel Blocker9.4%Dalfampridine Er100%Part D<11 patients+ 4 more classes in this area
Musculoskeletal
22.2%gamma-Aminobutyric Acid-ergic Agonist15%Baclofen100%Part D≥14 patientsCentral alpha-2 Adrenergic Agonist7.2%Tizanidine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2013–2025 per NIH RePORTER. The latest:
- Pooled analysis of multiple sclerosis findings on multi-site 7 Tesla MRI
University of Maryland Baltimore
FY2025$472,523R01NS122980 - Pooled analysis of multiple sclerosis findings on multi-site 7 Tesla MRI
University of Maryland Baltimore
FY2024$463,122R01NS122980 - Pooled analysis of multiple sclerosis findings on multi-site 7 Tesla MRI
University of Maryland Baltimore
FY2023$469,970R01NS122980
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”